4.8 Editorial Material

Visualizing Cancer

Journal

CANCER CELL
Volume 38, Issue 6, Pages 753-756

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2020.11.014

Keywords

-

Funding

  1. NCI NIH HHS [R01 CA244780] Funding Source: Medline

Ask authors/readers for more resources

Imaging has had a profound impact on our ability to understand and treat cancer. We invited some experts to discuss imaging approaches that can be used in various aspects of cancer research, from investigating the complexity and diversity of cancer cells and their environments to guiding clinical decision-making.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Multidisciplinary

Optimal Physicochemical Properties of Antibody-Nanoparticle Conjugates for Improved Tumor Targeting

Vincent Mittelheisser, Pierre Coliat, Eric Moeglin, Lilian Goepp, Jacky G. Goetz, Loic J. Charbonniere, Xavier Pivot, Alexandre Detappe

Summary: Tumor-targeted antibody/fragment-conjugated nanoparticles show promise in improving local delivery of small molecules. A meta-analysis of 161 studies confirmed that targeted nanoparticles had significantly higher tumor uptake compared to naked nanoparticles. The study also found that the choice of nanoparticle type, size, and antibody moiety affected tumor uptake.

ADVANCED MATERIALS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Noise sensitivity of 89Zr-Immuno-PET radiomics based on count-reduced clinical images

Ananthi Somasundaram, David Vallez Garcia, Elisabeth Pfaehler, Yvonne W. S. Jauw, Josee M. Zijlstra, Guus A. M. S. van Dongen, Willemien C. Menke-van der Houven Van Oordt, Marc C. Huisman, Elisabeth G. E. de Vries, Ronald Boellaard

Summary: This study investigates the impact of noise on radiomic features from Zr-89-Immuno-PET clinical images. It identifies features that are less affected by noise and can serve as potential prognostic and predictive biomarkers in Zr-89-Immuno-PET studies.

EJNMMI PHYSICS (2022)

Editorial Material Oncology

The first ones now, will later be last: understanding the importance of historical context when reading ESMO-MCBS scores

N. Cherny, U. Dafni, G. Pentheroudakis, M. Piccart, P. Zygoura, B. Gyawali, E. G. E. de Vries

ESMO OPEN (2022)

Editorial Material Oncology

Perspectives on imaging and immunotherapy: a review series

Elisabeth G. E. de Vries, Lawrence H. Schwartz

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Review Oncology

Molecular imaging to support cancer immunotherapy

Pim P. van de Donk, Sjoukje F. Oosting, Daan G. Knapen, Anthonie J. van der Wekken, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Derk-Jan A. de Groot, Elisabeth G. E. de Vries

Summary: The arrival of immune checkpoint inhibitors has revitalized the field of immuno-oncology. Molecular imaging techniques can provide valuable information for treatment decision-making by visualizing tumor and immune cell characteristics, as well as drug distribution.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Ontario, Canada. 7

Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries

Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.

CLINICAL CANCER RESEARCH (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations

Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard

Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.

MOLECULAR IMAGING AND BIOLOGY (2023)

Article Multidisciplinary Sciences

Mitigation of noise-induced bias of PET radiomic features

Ananthi Somasundaram, David Vallez Garcia, Elisabeth Pfaehler, Joyce van Sluis, Rudi A. J. O. Dierckx, Elisabeth G. E. de Vries, Ronald Boellaard

Summary: One major challenge in PET radiomics is its sensitivity to noise. This phantom study aims to identify the radiomic features that are robust to noise in terms of precision and accuracy and to explore some methods that might help to correct noise-induced bias.

PLOS ONE (2022)

Article Oncology

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

S. F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N. J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E. G. E. de Vries, M. Piccart, N. I. Cherny

Summary: This article discusses the importance of quality of life (QoL) data and quality assurance measures in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Through field testing and revision, a checklist consisting of four items was developed to ensure the reliability and clinical relevance of QoL data. Implementation of this checklist will facilitate objective and transparent decision making in the ESMO-MCBS scoring process.

ANNALS OF ONCOLOGY (2023)

Article Oncology

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER plus Breast Cancer Undergoing Treatment with Rintodestrant

Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt

Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Changes in survival in de novo metastatic cancer in an era of new medicines

Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank J. P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G. E. de Vries, Carin A. Uyl-de Groot, Sabine Siesling

Summary: This study evaluated the changes in survival of patients with de novo metastatic solid cancers over the past 30 years. The proportion of M1 disease and net survival rates varied among different cancer types. Better preventive measures and early detection are needed to reduce the incidence of metastatic disease.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Editorial Material Multidisciplinary Sciences

Towards evidence-based response criteria for cancer immunotherapy

Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G. E. de Vries

Summary: Early detection of immunotherapy-induced tumor response is crucial, but therapy-induced pseudoprogression can make it complicated. A consensus guideline called iRECIST, a modification of RECIST version 1.1, was developed. This article explores the next steps required to test its validity and proposes novel approaches for response criteria.

NATURE COMMUNICATIONS (2023)

Article Oncology

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale

Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.

CANCER MEDICINE (2023)

Article Oncology

Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey

Avram E. Denburg, Adam Fundytus, Muhammad Saghir Khan, Scott C. Howard, Federico Antillon-Klussmann, Manju Sengar, Dorothy Lombe, Wilma Hopman, Matthew Jalink, Bishal Gyawali, Dario Trapani, Felipe Roitberg, Elisabeth G. E. De Vries, Lorenzo Moja, Andre Ilbawi, Richard Sullivan, Christopher M. Booth

Summary: Access to essential cancer medicines, especially in low-income countries, remains a challenge in childhood cancer treatment. Most medicines deemed essential by pediatric oncologists are included on WHO's Model List of Essential Medicines for Children, but their accessibility and cost are still issues.

JCO GLOBAL ONCOLOGY (2022)

Review Oncology

Circulating extracellular vesicles and tumor cells: sticky partners in metastasis

Katerina Jerabkova-Roda, Amandine Dupas, Nael Osmani, Vincent Hyenne, Jacky G. Goetz

Summary: The intravascular behavior of tumor-derived extracellular vesicles (EVs) and circulating tumor cells (CTCs) plays a crucial role in the metastatic cascade. Understanding the role of cellular adhesion molecules (CAMs) and their endothelial ligands in dictating the arrest site and exit capacity of EVs/CTCs could provide insight into novel targets for therapies. Exploring the differences and similarities between CAMs on CTCs and EVs may help in understanding their role in organotropism of different cancer types.

TRENDS IN CANCER (2022)

No Data Available